AbCellera Biologics Inc. (ABCL) 10-Year Financial Performance & Capital Metrics

ABCL •

HealthcareBiotechnologyDrug Discovery and Antibody Platforms

AboutAbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.Show more

Revenue $75M +160.6%
EBITDA -$195M +10.5%
Net Income -$146M +10.1%
EPS (Diluted) -0.49 +10.9%
Gross Margin -
EBITDA Margin -259.47% +65.6%
Operating Margin -288.98% +73.5%
Net Margin -194.88% +65.5%
ROE -14.47% +1.9%
ROIC -16.78% +26.7%
Debt/Equity 0.14 +129.6%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 1.1x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Sales declining 20.3% over 5 years
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-20.27%

3Y-46.31%

TTM160.55%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM10.1%

EPS CAGR

10Y-

5Y-

3Y-

TTM12.5%

ROCE

10Y Avg-3.26%

5Y Avg-5.64%

3Y Avg-21.4%

Latest-23.49%

Peer Comparison

Drug Discovery and Antibody Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
REGNRegeneron Pharmaceuticals, Inc.	107.56B	781.67	18.84	0.99%	31.41%	14.41%	3.79%	0.09
CTMXCytomX Therapeutics, Inc.	430.14M	5.37	14.13	36.45%	24.66%	26.09%
PRTCPureTech Health plc	405.3M	16.77	8.39	44.98%	-495.91%	-8.53%		0.05
DNAGinkgo Bioworks Holdings, Inc.	327.53M	6.75	-1.20	-25.06%	-183.81%	-61.5%		0.82
BCYCBicycle Therapeutics plc	111.38M	5.73	-1.98	30.76%	-8.85%	-40.53%		0.01
CCCCC4 Therapeutics, Inc.	261.67M	2.70	-2.13	-100%		-40.92%		0.23
MOLNMolecular Partners AG	187.84M	5.02	-2.43	-29.38%	-10.87%	-63.06%		0.02
RXRXRecursion Pharmaceuticals, Inc.	1.94B	3.67	-2.55	26.92%	-8.65%	-57.01%		0.07

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	8.83M	11.61M	233.16M	375.2M	485.42M	38.02M	28.83M	75.13M
Revenue Growth %	-	31.49%	1907.88%	60.92%	29.38%	-92.17%	-24.17%	160.56%
Cost of Goods Sold+	5.8M	0	27.14M	45.52M	66.44M	0	0	0
COGS % of Revenue	65.71%	-	11.64%	12.13%	13.69%	-	-	-
Gross Profit+	3.03M	11.61M	206.01M	329.69M	418.99M	38.02M	28.83M	0
Gross Margin %	34.29%	100%	88.36%	87.87%	86.31%	100%	100%	-
Gross Profit Growth %	-	283.49%	1674.13%	60.03%	27.09%	-90.92%	-24.17%	-100%
Operating Expenses+	7.99M	15.73M	49.98M	125.27M	202.48M	275.23M	343.6M	292.23M
OpEx % of Revenue	90.48%	135.45%	21.44%	33.39%	41.71%	723.82%	1191.69%	388.98%
Selling, General & Admin	2.86M	4.01M	15.75M	48.76M	66.75M	75.18M	85.49M	83.23M
SG&A % of Revenue	32.42%	34.55%	6.76%	13%	13.75%	197.71%	296.5%	110.79%
Research & Development	5.8M	10.11M	29.39M	62.06M	107.88M	175.66M	167.26M	186.83M
R&D % of Revenue	65.71%	87.09%	12.61%	16.54%	22.22%	461.95%	580.1%	248.68%
Other Operating Expenses	-675.51K	1.6M	4.84M	14.45M	27.84M	24.39M	90.85M	22.17M
Operating Income+	-753K	-4.12M	156.03M	204.41M	216.51M	-237.21M	-314.77M	-217.1M
Operating Margin %	-8.53%	-35.45%	66.92%	54.48%	44.6%	-623.82%	-1091.69%	-288.98%
Operating Income Growth %	-	-446.75%	3889.92%	31.01%	5.92%	-209.56%	-32.7%	31.03%
EBITDA+	165.46K	-2.27M	161.3M	221.66M	249.61M	-206.31M	-217.77M	-194.93M
EBITDA Margin %	1.87%	-19.55%	69.18%	59.08%	51.42%	-542.57%	-755.27%	-259.47%
EBITDA Growth %	-	-1471.94%	7205.81%	37.42%	12.61%	-182.65%	-5.55%	10.49%
D&A (Non-Cash Add-back)	918.46K	1.85M	5.27M	17.25M	33.1M	30.89M	97M	22.17M
EBIT	521K	-2M	164.34M	221.9M	227.06M	-223.05M	-301.15M	-177.59M
Net Interest Income+	-170K	-54K	-6.22M	-1.9M	12.03M	42.25M	38.47M	28.33M
Interest Income	42K	155K	293K	3.33M	16.08M	42.25M	38.47M	28.33M
Interest Expense	212K	209K	6.51M	5.22M	4.04M	0	0	0
Other Income/Expense	1.06M	1.91M	1.8M	14.74M	22.59M	63.18M	114.37M	39.51M
Pretax Income+	309K	-2.21M	157.83M	219.15M	239.1M	-174.03M	-200.4M	-177.59M
Pretax Margin %	3.5%	-19.04%	67.69%	58.41%	49.26%	-457.67%	-695.02%	-236.39%
Income Tax+	0	0	38.91M	65.69M	80.58M	-27.63M	-37.54M	-31.18M
Effective Tax Rate %	100%	100%	75.34%	70.03%	66.3%	84.12%	81.27%	82.44%
Net Income+	309K	-2.21M	118.92M	153.46M	158.52M	-146.4M	-162.86M	-146.41M
Net Margin %	3.5%	-19.04%	51%	40.9%	32.66%	-385%	-564.83%	-194.88%
Net Income Growth %	-	-815.53%	5478.47%	29.05%	3.29%	-192.35%	-11.24%	10.1%
Net Income (Continuing)	309K	-2.21M	118.92M	153.46M	158.52M	-146.4M	-162.86M	-146.41M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.00	-0.01	0.45	0.48	0.50	-0.51	-0.55	-0.49
EPS Growth %	-	-	4468.93%	6.67%	4.17%	-202%	-7.84%	10.91%
EPS (Basic)	0.00	-0.01	0.32	0.56	0.56	-0.51	-0.55	-0.49
Diluted Shares Outstanding	151.04M	237.72M	263.13M	318.29M	314.83M	289.17M	294.33M	298.71M
Basic Shares Outstanding	151.06M	215.41M	267.82M	275.76M	285.06M	289.17M	294.33M	298.71M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	15.16M	12.64M	813.33M	929.8M	1.03B	871.99M	751.37M	728.23M
Cash & Short-Term Investments	10.44M	7.55M	594.12M	722.98M	886.49M	760.59M	625.61M	533.83M
Cash Only	10.44M	7.55M	594.12M	476.14M	386.54M	133.32M	156.32M	128.51M
Short-Term Investments	0	0	0	246.84M	499.95M	627.26M	469.29M	405.31M
Accounts Receivable	1.4M	2.12M	213.73M	160.58M	38.59M	64.38M	92.13M	58.29M
Days Sales Outstanding	58.05	66.76	334.59	156.21	29.02	618	1.17K	283.21
Inventory	0	163K	1.41M	1.67M	1.53M	1.11M	0	0
Days Inventory Outstanding	-	-	18.93	13.41	8.42	-	-	-
Other Current Assets	2.76M	2.25M	0	39.28M	89.82M	45.91M	33.63M	136.11M
Total Non-Current Assets+	6.33M	10.85M	192.21M	388.77M	515.42M	616.11M	609.18M	-99.51M
Property, Plant & Equipment	6.33M	8.48M	17.92M	111.62M	217.25M	287.7M	340.43M	428M
Fixed Asset Turnover	1.40x	1.37x	13.01x	3.36x	2.23x	0.13x	0.08x	0.18x
Goodwill	0	0	31.5M	47.81M	47.81M	47.81M	47.81M	47.81M
Intangible Assets	0	0	115.15M	148.39M	131.5M	120.42M	42.11M	38.38M
Long-Term Investments	0	0	20.03M	50.31M	72.52M	65.94M	82.3M	62.58M
Other Non-Current Assets	0	2.37M	1.71M	23.23M	41.03M	94.24M	96.54M	-676.28M
Total Assets+	21.49M	23.49M	1.01B	1.32B	1.54B	1.49B	1.36B	628.72M
Asset Turnover	0.41x	0.49x	0.23x	0.28x	0.32x	0.03x	0.02x	0.12x
Asset Growth %	-	9.29%	4181.06%	31.13%	16.86%	-3.43%	-8.57%	-53.79%
Total Current Liabilities+	6.43M	7.89M	103.49M	120.68M	118.32M	119.01M	76.61M	64.31M
Accounts Payable	1.52M	1.64M	7.32M	14.92M	14.83M	25.51M	34.35M	0
Days Payables Outstanding	95.49	-	98.43	119.68	81.47	-	-	-
Short-Term Debt	2.53M	2.47M	190K	0	0	0	0	0
Deferred Revenue (Current)	2.33M	0	7.53M	7.54M	21.61M	18.96M	21.18M	13.53M
Other Current Liabilities	50.12K	3.37M	9.08M	54.85M	69.84M	60.68M	8.09M	50.78M
Current Ratio	2.36x	1.60x	7.86x	7.70x	8.67x	7.33x	9.81x	11.32x
Quick Ratio	2.36x	1.58x	7.85x	7.69x	8.65x	7.32x	9.81x	11.32x
Cash Conversion Cycle	-	-	255.09	49.94	-44.03	-	-	-
Total Non-Current Liabilities+	3.45M	5.34M	71.54M	172.16M	189.31M	216.76M	227.86M	261.43M
Long-Term Debt	911.22K	1.36M	2.2M	0	0	0	0	137.4M
Capital Lease Obligations	0	2.64M	3.71M	36.41M	76.67M	71.22M	60.74M	0
Deferred Tax Liabilities	0	0	26.16M	37.37M	33.18M	30.61M	10.05M	9.12M
Other Non-Current Liabilities	277.13K	1.34M	13.57M	37.62M	19.14M	10.82M	1.47M	114.91M
Total Liabilities	9.88M	13.24M	175.03M	292.84M	307.63M	335.78M	304.47M	325.74M
Total Debt+	3.44M	6.89M	6.78M	40.06M	82.26M	77.38M	65.36M	137.4M
Net Debt	-7M	-662K	-587.34M	-436.08M	-304.28M	-55.94M	-90.96M	8.89M
Debt / Equity	0.30x	0.67x	0.01x	0.04x	0.07x	0.07x	0.06x	0.14x
Debt / EBITDA	20.81x	-	0.04x	0.18x	0.33x	-	-	-
Net Debt / EBITDA	-42.32x	-	-3.64x	-1.97x	-1.22x	-	-	-
Interest Coverage	-3.55x	-19.70x	23.96x	39.12x	53.53x	-	-	-
Total Equity+	11.61M	10.25M	830.51M	1.03B	1.23B	1.15B	1.06B	966.9M
Equity Growth %	-	-11.69%	8000.94%	23.51%	20.23%	-6.56%	-8.35%	-8.44%
Book Value per Share	0.08	0.04	3.16	3.22	3.92	3.98	3.59	3.24
Total Shareholders' Equity	11.61M	10.25M	830.51M	1.03B	1.23B	1.15B	1.06B	966.9M
Common Stock	5.07M	5.12M	710.39M	722.43M	734.37M	753.2M	777.17M	802.34M
Retained Earnings	-2.5M	-4.72M	114.2M	267.67M	426.19M	279.79M	116.93M	-29.48M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	280K	-1.39M	-1.72M	-4.38M	-4.23M
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	3.56M	2.69M	22.69M	244.58M	277.36M	-43.88M	-108.56M	-131.29M
Operating CF Margin %	40.37%	23.2%	9.73%	65.19%	57.14%	-115.39%	-376.5%	-174.76%
Operating CF Growth %	-	-24.43%	742.24%	977.94%	13.4%	-115.82%	-147.41%	-20.95%
Net Income	309K	-2.21M	118.92M	153.46M	158.52M	-146.4M	-162.86M	-146.41M
Depreciation & Amortization	918K	1.85M	5.27M	17.25M	33.1M	30.89M	97M	22.17M
Stock-Based Compensation	615K	890K	8.4M	30.65M	49.48M	64.18M	67.58M	55.79M
Deferred Taxes	0	0	2.1M	-2.02M	-2.11M	1.96M	0	0
Other Non-Cash Items	-188K	194K	4.71M	3.57M	8.55M	-7.74M	-84.44M	-62.85M
Working Capital Changes	1.91M	1.97M	-116.7M	41.67M	29.82M	13.22M	-25.84M	0
Change in Receivables	-477K	-1.8M	-203.02M	22.48M	-22.71M	-45.93M	-75.12M	0
Change in Inventory	-897.77K	0	0	0	0	18.25M	0	0
Change in Payables	180K	150K	6.6M	1.4M	1.07M	-15.1M	10.63M	3.46M
Cash from Investing+	-5.31M	-5.78M	-119.78M	-332.25M	-352.63M	-221.11M	121.41M	87.75M
Capital Expenditures	-5.31M	-4M	-9.67M	-58.45M	-72.66M	-77.51M	-78.4M	-42.77M
CapEx % of Revenue	60.1%	34.42%	4.15%	15.58%	14.97%	203.83%	271.9%	56.93%
Acquisitions	0	0	-106.89M	-11.46M	-25.68M	-13.69M	-19.63M	0
Investments	-	-	-	-	-	-	-	-
Other Investing	0	-1.78M	-3.22M	32.62M	16.43M	25.31M	35.71M	566.57M
Cash from Financing+	12.19M	195K	683.65M	-3.89M	-1.63M	10.36M	12.77M	14.08M
Debt Issued (Net)	1.98M	181K	85.15M	-951K	2.75M	11.59M	13.5M	0
Equity Issued (Net)	1000K	14.16K	1000K	1000K	0	0	0	0
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0
Other Financing	37K	25K	1M	-7.55M	-4.38M	-1.23M	-729K	14.08M
Net Change in Cash	10.44M	-2.89M	586.56M	-92.97M	-86.49M	-254.04M	23M	-28.37M
Free Cash Flow+	-1.74M	-1.3M	8.02M	186.13M	204.7M	-121.38M	-186.95M	-174.07M
FCF Margin %	-19.73%	-11.22%	3.44%	49.61%	42.17%	-319.22%	-648.4%	-231.69%
FCF Growth %	-	25.2%	715.27%	2221.72%	9.98%	-159.3%	-54.02%	6.89%
FCF per Share	-0.01	-0.01	0.03	0.58	0.65	-0.42	-0.64	-0.58
FCF Conversion (FCF/Net Income)	11.54x	-1.22x	0.19x	1.59x	1.75x	0.30x	0.67x	0.90x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	2.66%	-20.23%	28.29%	16.53%	14.03%	-12.27%	-14.75%	-14.47%
Return on Invested Capital (ROIC)	-	-43.5%	92.6%	36.82%	21.39%	-17.57%	-22.9%	-16.78%
Gross Margin	34.29%	100%	88.36%	87.87%	86.31%	100%	100%	-
Net Margin	3.5%	-19.04%	51%	40.9%	32.66%	-385%	-564.83%	-194.88%
Debt / Equity	0.30x	0.67x	0.01x	0.04x	0.07x	0.07x	0.06x	0.14x
Interest Coverage	-3.55x	-19.70x	23.96x	39.12x	53.53x	-	-	-
FCF Conversion	11.54x	-1.22x	0.19x	1.59x	1.75x	0.30x	0.67x	0.90x
Revenue Growth	-	31.49%	1907.88%	60.92%	29.38%	-92.17%	-24.17%	160.56%

US Stock Screener

...

AbCellera Biologics Inc. (ABCL) 10-Year Financial Performance & Capital Metrics

ABCL •

HealthcareBiotechnologyDrug Discovery and Antibody Platforms

Revenue $75M +160.6%
EBITDA -$195M +10.5%
Net Income -$146M +10.1%
EPS (Diluted) -0.49 +10.9%
Gross Margin -
EBITDA Margin -259.47% +65.6%
Operating Margin -288.98% +73.5%
Net Margin -194.88% +65.5%
ROE -14.47% +1.9%
ROIC -16.78% +26.7%
Debt/Equity 0.14 +129.6%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 1.1x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Sales declining 20.3% over 5 years
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-20.27%

3Y-46.31%

TTM160.55%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM10.1%

EPS CAGR

10Y-

5Y-

3Y-

TTM12.5%

ROCE

10Y Avg-3.26%

5Y Avg-5.64%

3Y Avg-21.4%

Latest-23.49%

Peer Comparison

Drug Discovery and Antibody Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
REGNRegeneron Pharmaceuticals, Inc.	107.56B	781.67	18.84	0.99%	31.41%	14.41%	3.79%	0.09
CTMXCytomX Therapeutics, Inc.	430.14M	5.37	14.13	36.45%	24.66%	26.09%
PRTCPureTech Health plc	405.3M	16.77	8.39	44.98%	-495.91%	-8.53%		0.05
DNAGinkgo Bioworks Holdings, Inc.	327.53M	6.75	-1.20	-25.06%	-183.81%	-61.5%		0.82
BCYCBicycle Therapeutics plc	111.38M	5.73	-1.98	30.76%	-8.85%	-40.53%		0.01
CCCCC4 Therapeutics, Inc.	261.67M	2.70	-2.13	-100%		-40.92%		0.23
MOLNMolecular Partners AG	187.84M	5.02	-2.43	-29.38%	-10.87%	-63.06%		0.02
RXRXRecursion Pharmaceuticals, Inc.	1.94B	3.67	-2.55	26.92%	-8.65%	-57.01%		0.07

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	8.83M	11.61M	233.16M	375.2M	485.42M	38.02M	28.83M	75.13M
Revenue Growth %	-	31.49%	1907.88%	60.92%	29.38%	-92.17%	-24.17%	160.56%
Cost of Goods Sold+	5.8M	0	27.14M	45.52M	66.44M	0	0	0
COGS % of Revenue	65.71%	-	11.64%	12.13%	13.69%	-	-	-
Gross Profit+	3.03M	11.61M	206.01M	329.69M	418.99M	38.02M	28.83M	0
Gross Margin %	34.29%	100%	88.36%	87.87%	86.31%	100%	100%	-
Gross Profit Growth %	-	283.49%	1674.13%	60.03%	27.09%	-90.92%	-24.17%	-100%
Operating Expenses+	7.99M	15.73M	49.98M	125.27M	202.48M	275.23M	343.6M	292.23M
OpEx % of Revenue	90.48%	135.45%	21.44%	33.39%	41.71%	723.82%	1191.69%	388.98%
Selling, General & Admin	2.86M	4.01M	15.75M	48.76M	66.75M	75.18M	85.49M	83.23M
SG&A % of Revenue	32.42%	34.55%	6.76%	13%	13.75%	197.71%	296.5%	110.79%
Research & Development	5.8M	10.11M	29.39M	62.06M	107.88M	175.66M	167.26M	186.83M
R&D % of Revenue	65.71%	87.09%	12.61%	16.54%	22.22%	461.95%	580.1%	248.68%
Other Operating Expenses	-675.51K	1.6M	4.84M	14.45M	27.84M	24.39M	90.85M	22.17M
Operating Income+	-753K	-4.12M	156.03M	204.41M	216.51M	-237.21M	-314.77M	-217.1M
Operating Margin %	-8.53%	-35.45%	66.92%	54.48%	44.6%	-623.82%	-1091.69%	-288.98%
Operating Income Growth %	-	-446.75%	3889.92%	31.01%	5.92%	-209.56%	-32.7%	31.03%
EBITDA+	165.46K	-2.27M	161.3M	221.66M	249.61M	-206.31M	-217.77M	-194.93M
EBITDA Margin %	1.87%	-19.55%	69.18%	59.08%	51.42%	-542.57%	-755.27%	-259.47%
EBITDA Growth %	-	-1471.94%	7205.81%	37.42%	12.61%	-182.65%	-5.55%	10.49%
D&A (Non-Cash Add-back)	918.46K	1.85M	5.27M	17.25M	33.1M	30.89M	97M	22.17M
EBIT	521K	-2M	164.34M	221.9M	227.06M	-223.05M	-301.15M	-177.59M
Net Interest Income+	-170K	-54K	-6.22M	-1.9M	12.03M	42.25M	38.47M	28.33M
Interest Income	42K	155K	293K	3.33M	16.08M	42.25M	38.47M	28.33M
Interest Expense	212K	209K	6.51M	5.22M	4.04M	0	0	0
Other Income/Expense	1.06M	1.91M	1.8M	14.74M	22.59M	63.18M	114.37M	39.51M
Pretax Income+	309K	-2.21M	157.83M	219.15M	239.1M	-174.03M	-200.4M	-177.59M
Pretax Margin %	3.5%	-19.04%	67.69%	58.41%	49.26%	-457.67%	-695.02%	-236.39%
Income Tax+	0	0	38.91M	65.69M	80.58M	-27.63M	-37.54M	-31.18M
Effective Tax Rate %	100%	100%	75.34%	70.03%	66.3%	84.12%	81.27%	82.44%
Net Income+	309K	-2.21M	118.92M	153.46M	158.52M	-146.4M	-162.86M	-146.41M
Net Margin %	3.5%	-19.04%	51%	40.9%	32.66%	-385%	-564.83%	-194.88%
Net Income Growth %	-	-815.53%	5478.47%	29.05%	3.29%	-192.35%	-11.24%	10.1%
Net Income (Continuing)	309K	-2.21M	118.92M	153.46M	158.52M	-146.4M	-162.86M	-146.41M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.00	-0.01	0.45	0.48	0.50	-0.51	-0.55	-0.49
EPS Growth %	-	-	4468.93%	6.67%	4.17%	-202%	-7.84%	10.91%
EPS (Basic)	0.00	-0.01	0.32	0.56	0.56	-0.51	-0.55	-0.49
Diluted Shares Outstanding	151.04M	237.72M	263.13M	318.29M	314.83M	289.17M	294.33M	298.71M
Basic Shares Outstanding	151.06M	215.41M	267.82M	275.76M	285.06M	289.17M	294.33M	298.71M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	15.16M	12.64M	813.33M	929.8M	1.03B	871.99M	751.37M	728.23M
Cash & Short-Term Investments	10.44M	7.55M	594.12M	722.98M	886.49M	760.59M	625.61M	533.83M
Cash Only	10.44M	7.55M	594.12M	476.14M	386.54M	133.32M	156.32M	128.51M
Short-Term Investments	0	0	0	246.84M	499.95M	627.26M	469.29M	405.31M
Accounts Receivable	1.4M	2.12M	213.73M	160.58M	38.59M	64.38M	92.13M	58.29M
Days Sales Outstanding	58.05	66.76	334.59	156.21	29.02	618	1.17K	283.21
Inventory	0	163K	1.41M	1.67M	1.53M	1.11M	0	0
Days Inventory Outstanding	-	-	18.93	13.41	8.42	-	-	-
Other Current Assets	2.76M	2.25M	0	39.28M	89.82M	45.91M	33.63M	136.11M
Total Non-Current Assets+	6.33M	10.85M	192.21M	388.77M	515.42M	616.11M	609.18M	-99.51M
Property, Plant & Equipment	6.33M	8.48M	17.92M	111.62M	217.25M	287.7M	340.43M	428M
Fixed Asset Turnover	1.40x	1.37x	13.01x	3.36x	2.23x	0.13x	0.08x	0.18x
Goodwill	0	0	31.5M	47.81M	47.81M	47.81M	47.81M	47.81M
Intangible Assets	0	0	115.15M	148.39M	131.5M	120.42M	42.11M	38.38M
Long-Term Investments	0	0	20.03M	50.31M	72.52M	65.94M	82.3M	62.58M
Other Non-Current Assets	0	2.37M	1.71M	23.23M	41.03M	94.24M	96.54M	-676.28M
Total Assets+	21.49M	23.49M	1.01B	1.32B	1.54B	1.49B	1.36B	628.72M
Asset Turnover	0.41x	0.49x	0.23x	0.28x	0.32x	0.03x	0.02x	0.12x
Asset Growth %	-	9.29%	4181.06%	31.13%	16.86%	-3.43%	-8.57%	-53.79%
Total Current Liabilities+	6.43M	7.89M	103.49M	120.68M	118.32M	119.01M	76.61M	64.31M
Accounts Payable	1.52M	1.64M	7.32M	14.92M	14.83M	25.51M	34.35M	0
Days Payables Outstanding	95.49	-	98.43	119.68	81.47	-	-	-
Short-Term Debt	2.53M	2.47M	190K	0	0	0	0	0
Deferred Revenue (Current)	2.33M	0	7.53M	7.54M	21.61M	18.96M	21.18M	13.53M
Other Current Liabilities	50.12K	3.37M	9.08M	54.85M	69.84M	60.68M	8.09M	50.78M
Current Ratio	2.36x	1.60x	7.86x	7.70x	8.67x	7.33x	9.81x	11.32x
Quick Ratio	2.36x	1.58x	7.85x	7.69x	8.65x	7.32x	9.81x	11.32x
Cash Conversion Cycle	-	-	255.09	49.94	-44.03	-	-	-
Total Non-Current Liabilities+	3.45M	5.34M	71.54M	172.16M	189.31M	216.76M	227.86M	261.43M
Long-Term Debt	911.22K	1.36M	2.2M	0	0	0	0	137.4M
Capital Lease Obligations	0	2.64M	3.71M	36.41M	76.67M	71.22M	60.74M	0
Deferred Tax Liabilities	0	0	26.16M	37.37M	33.18M	30.61M	10.05M	9.12M
Other Non-Current Liabilities	277.13K	1.34M	13.57M	37.62M	19.14M	10.82M	1.47M	114.91M
Total Liabilities	9.88M	13.24M	175.03M	292.84M	307.63M	335.78M	304.47M	325.74M
Total Debt+	3.44M	6.89M	6.78M	40.06M	82.26M	77.38M	65.36M	137.4M
Net Debt	-7M	-662K	-587.34M	-436.08M	-304.28M	-55.94M	-90.96M	8.89M
Debt / Equity	0.30x	0.67x	0.01x	0.04x	0.07x	0.07x	0.06x	0.14x
Debt / EBITDA	20.81x	-	0.04x	0.18x	0.33x	-	-	-
Net Debt / EBITDA	-42.32x	-	-3.64x	-1.97x	-1.22x	-	-	-
Interest Coverage	-3.55x	-19.70x	23.96x	39.12x	53.53x	-	-	-
Total Equity+	11.61M	10.25M	830.51M	1.03B	1.23B	1.15B	1.06B	966.9M
Equity Growth %	-	-11.69%	8000.94%	23.51%	20.23%	-6.56%	-8.35%	-8.44%
Book Value per Share	0.08	0.04	3.16	3.22	3.92	3.98	3.59	3.24
Total Shareholders' Equity	11.61M	10.25M	830.51M	1.03B	1.23B	1.15B	1.06B	966.9M
Common Stock	5.07M	5.12M	710.39M	722.43M	734.37M	753.2M	777.17M	802.34M
Retained Earnings	-2.5M	-4.72M	114.2M	267.67M	426.19M	279.79M	116.93M	-29.48M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	280K	-1.39M	-1.72M	-4.38M	-4.23M
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	3.56M	2.69M	22.69M	244.58M	277.36M	-43.88M	-108.56M	-131.29M
Operating CF Margin %	40.37%	23.2%	9.73%	65.19%	57.14%	-115.39%	-376.5%	-174.76%
Operating CF Growth %	-	-24.43%	742.24%	977.94%	13.4%	-115.82%	-147.41%	-20.95%
Net Income	309K	-2.21M	118.92M	153.46M	158.52M	-146.4M	-162.86M	-146.41M
Depreciation & Amortization	918K	1.85M	5.27M	17.25M	33.1M	30.89M	97M	22.17M
Stock-Based Compensation	615K	890K	8.4M	30.65M	49.48M	64.18M	67.58M	55.79M
Deferred Taxes	0	0	2.1M	-2.02M	-2.11M	1.96M	0	0
Other Non-Cash Items	-188K	194K	4.71M	3.57M	8.55M	-7.74M	-84.44M	-62.85M
Working Capital Changes	1.91M	1.97M	-116.7M	41.67M	29.82M	13.22M	-25.84M	0
Change in Receivables	-477K	-1.8M	-203.02M	22.48M	-22.71M	-45.93M	-75.12M	0
Change in Inventory	-897.77K	0	0	0	0	18.25M	0	0
Change in Payables	180K	150K	6.6M	1.4M	1.07M	-15.1M	10.63M	3.46M
Cash from Investing+	-5.31M	-5.78M	-119.78M	-332.25M	-352.63M	-221.11M	121.41M	87.75M
Capital Expenditures	-5.31M	-4M	-9.67M	-58.45M	-72.66M	-77.51M	-78.4M	-42.77M
CapEx % of Revenue	60.1%	34.42%	4.15%	15.58%	14.97%	203.83%	271.9%	56.93%
Acquisitions	0	0	-106.89M	-11.46M	-25.68M	-13.69M	-19.63M	0
Investments	-	-	-	-	-	-	-	-
Other Investing	0	-1.78M	-3.22M	32.62M	16.43M	25.31M	35.71M	566.57M
Cash from Financing+	12.19M	195K	683.65M	-3.89M	-1.63M	10.36M	12.77M	14.08M
Debt Issued (Net)	1.98M	181K	85.15M	-951K	2.75M	11.59M	13.5M	0
Equity Issued (Net)	1000K	14.16K	1000K	1000K	0	0	0	0
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0
Other Financing	37K	25K	1M	-7.55M	-4.38M	-1.23M	-729K	14.08M
Net Change in Cash	10.44M	-2.89M	586.56M	-92.97M	-86.49M	-254.04M	23M	-28.37M
Free Cash Flow+	-1.74M	-1.3M	8.02M	186.13M	204.7M	-121.38M	-186.95M	-174.07M
FCF Margin %	-19.73%	-11.22%	3.44%	49.61%	42.17%	-319.22%	-648.4%	-231.69%
FCF Growth %	-	25.2%	715.27%	2221.72%	9.98%	-159.3%	-54.02%	6.89%
FCF per Share	-0.01	-0.01	0.03	0.58	0.65	-0.42	-0.64	-0.58
FCF Conversion (FCF/Net Income)	11.54x	-1.22x	0.19x	1.59x	1.75x	0.30x	0.67x	0.90x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	2.66%	-20.23%	28.29%	16.53%	14.03%	-12.27%	-14.75%	-14.47%
Return on Invested Capital (ROIC)	-	-43.5%	92.6%	36.82%	21.39%	-17.57%	-22.9%	-16.78%
Gross Margin	34.29%	100%	88.36%	87.87%	86.31%	100%	100%	-
Net Margin	3.5%	-19.04%	51%	40.9%	32.66%	-385%	-564.83%	-194.88%
Debt / Equity	0.30x	0.67x	0.01x	0.04x	0.07x	0.07x	0.06x	0.14x
Interest Coverage	-3.55x	-19.70x	23.96x	39.12x	53.53x	-	-	-
FCF Conversion	11.54x	-1.22x	0.19x	1.59x	1.75x	0.30x	0.67x	0.90x
Revenue Growth	-	31.49%	1907.88%	60.92%	29.38%	-92.17%	-24.17%	160.56%

AbCellera Biologics Inc. (ABCL) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare ABCL vs Peers

vs REGN

vs CNTA

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

AbCellera Biologics Inc. (ABCL) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare ABCL vs Peers

vs REGN

vs CNTA

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios